Investigating the importance of charged residues in lantibiotics

Bioengineered Bugs

Volumn 1, Issue 5, 2010, Pages 345-351

  Suda, Srinivas ^a   Hill, Colin ^a,b   Cotter, Paul D ^b,c   Paul Ross, R ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c TEAGASC FOOD RESEARCH CENTRE   (Ireland)

Author keywords

Antimicrobial peptides; Bioengineering; Charged residue; Lacticin 3147; Lantibiotics

Indexed keywords

LACTICIN 3147; LANTIBIOTIC; NISIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOENGINEERING; ELECTRIC ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIOCINS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

POSIBACTERIA;

EID: 78449298034     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.1.5.12353     Document Type: Article

References (44)

1. Deegan LH, Suda S, Lawton EM, Draper LA, Hugenholtz F, Peschel A, et al. Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147. Microbiol Biotechnol 2010; 3:222-34.
2. Cotter PD, O'Connor PM, Draper LA, Lawton EM, Deegan LH, Hill C, et al. Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci USA 2005; 102:18584-9.
3. Chatterjee C, Paul M, Xie L, van der Donk WA. Biosynthesis and mode of action of lantibiotics. Chem Rev 2005; 105:633-84.
4. Pag U, Sahl HG. Multiple activities in lantibiotics- models for the design of novel antibiotics? Curr Pharm Des 2002; 8:815-33.
5. Xie L, van der Donk WA. Post-translational modifications during lantibiotic biosynthesis. Curr Opin Chem Biol 2004; 8:498-507.
6. Bierbaum G, Sahl HG. Lantibiotics-unusually modified bacteriocin-like peptides from gram positive bacteria. Zentralbl Bakteriol 1993; 278:1-22.
7. Ryan MP, Jack RW, Josten M, Sahl HG, Jung G, Ross RP, et al. Extensive post-translational modification, including serine to D-alanine conversion, in the twocomponent lantibiotic, lacticin 3147. J Biol Chem 1999; 274:37544-50.
8. Lawton EM, Ross RP, Hill C, Cotter PD. Twopeptide lantibiotics: a medical perspective. Mini Rev Med Chem 2007; 7:1236-47.
9. Lawton EM, Cotter PD, Hill C, Ross RP. Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol Lett 2007; 267:64-71.
10. Cooper LE, McClerren AL, Chary A, van der Donk WA. Structure-activity relationship studies of the two-component lantibiotic haloduracin. Chem Biol 2008; 15:1035-45.
11. Navaratna MA, Sahl HG, Tagg JR. Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene. Infect Immun 1999; 67:4268-71.
12. Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF. Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 2001; 147:643 51.
13. O'Connor EB, Cotter PD, O'Connor P, O'Sullivan O, Tagg JR, Ross RP, et al. Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity. BMC Microbiol 2007; 7:24.
14. Begley M, Cotter PD, Hill C, Ross RP. Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microbiol 2009; 75:5451-60.
15. Yonezawa H, Kuramitsu HK. Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob Agents Chemother 2005; 49:541-8.
16. Hyink O, Balakrishnan M, Tagg JR. Streptococcus rattus strain BHT produces both a class I two-component lantibiotic and a class II bacteriocin. FEMS Microbiol Lett 2005; 252:235 41.
17. Wiedemann I, Bottiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, et al. The mode of action of the lantibiotic lacticin 3147-a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 2006; 61:285-96.
18. Morgan SM, O'Connor PM, Cotter PD, Ross RP, Hill C. Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother 2005; 49:2606-11.
19. Navaratna MA, Sahl HG, Tagg JR. Two-component anti-Staphylococcus aureus lantibiotic activity produced by Staphylococcus aureus C55. Appl Environ Microbiol 1998; 64:4803-8.
20. Oman TJ, van der Donk WA. Insights into the mode of action of the two-peptide lantibiotic haloduracin. ACS Chem Biol 2009; 4:865-74.
21. Jung G. Lantibiotics-Ribosomally synthesized biologically active polypeptides containing sulfide bridges and alpha,beta-didehydroamino acids. Angewandte Chemie (Int Ed Engl) 1991; 30:1051-192.
22. Wu Z, Li X, de Leeuw E, Ericksen B, Lu W. Why is the Arg5-Glu13 salt bridge conserved in mammalian alpha-defensins? J Biol Chem 2005; 280:43039-47.
23. Hancock RE, Lehrer R. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998; 16:82-8.
24. Jiang Z, Vasil AI, Hale JD, Hancock RE, Vasil ML, Hodges RS. Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides. Biopolymers 2008; 90:369-83.
25. Kuipers OP, Bierbaum G, Ottenwalder B, Dodd HM, Horn N, Metzger J, et al. Protein engineering of lantibiotics. Antonie Van Leeuwenhoek 1996; 69:161-9.
26. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 2001; 276:1772-9.
27. Van Kraaij C, Breukink E, Rollema HS, Siezen RJ, Demel RA, De Kruijff B, et al. Influence of charge differences in the C-terminal part of nisin on antimicrobial activity and signaling capacity. Eur J Biochem 1997; 247:114-20.
28. Yuan J, Zhang ZZ, Chen XZ, Yang W, Huan LD. Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. Appl icrobiol Biotechnol 2004; 64:806-15.
29. Field D, Connor PM, Cotter PD, Hill C, Ross RP. he generation of nisin variants with enhanced ctivity against specific gram-positive pathogens. Mol Microbiol 2008; 69:218-30.
30. Rink R, Wierenga J, Kuipers A, Kluskens LD, Driessen AJ, Kuipers OP, et al. Dissection and modulation of the four distinct activities of nisin by mutagenesis of rings A and B and by C terminal truncation. Appl Environ Microbiol 2007; 73:5809-16.
31. Bierbaum G, Reis M, Szekat C, Sahl HG. Construction of an expression system for engineering of the lantibiotic Pep5. Appl Environ Microbiol 1994; 60:4332-8.
32. Cotter PD, Hill C, Ross RP. Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci 2005; 6:61-75.
33. Cotter PD, Deegan LH, Lawton EM, Draper LA, O'Connor PM, Hill C, et al. Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol 2006; 62:735-47.
34. Appleyard AN, Choi S, Read DM, Lightfoot A, Boakes S, Hoffmann A, et al. Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol 2009; 16:490-8.
35. Islam MR, Shioya K, Nagao J, Nishie M, Jikuya H, Zendo T, et al. Evaluation of essential and variable residues of nukacin ISK-1 by NNK scanning. Mol Microbiol 2009; 72:1438-47.
36. Chatterjee C, Patton GC, Cooper L, Paul M, van der Donk WA. Engineering dehydro amino acids and thioethers into peptides using lacticin 481 synthetase. Chem Biol 2006; 13:1109 17.
37. McAuliffe O, Ryan MP, Ross RP, Hill C, Breeuwer P, Abee T. Lacticin 3147, a broad spectrum bacteriocin which selectively dissipates the membrane potential. Appl Environ Microbiol 1998; 64:439-45.
38. Chatterjee S, Lad SJ, Phansalkar MS, Rupp RH, Ganguli BN, Fehlhaber HW, et al. Mersacidin, a new antibiotic from Bacillus. Fermentation, isolation, purification and chemical characterization. J Antibiot (Tokyo) 1992; 45:832-8.
39. Zimmermann N, Metzger JW, Jung G. The tetracyclic lantibiotic actagardine. 1H-NMR and 13CNMR assignments and revised primary structure. Eur J Biochem 1995; 228:786-97.
40. Szekat C, Jack RW, Skutlarek D, Farber H, Bierbaum G. Construction of an expression system for sitedirected mutagenesis of the lantibiotic mersacidin. Appl Environ Microbiol 2003; 69:3777-83.
41. Boakes S, Cortes J, Appleyard AN, Rudd BA, Dawson MJ. Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system. Mol Microbiol 2009; 72:1126-36.
42. Dischinger J, Josten M, Szekat C, Sahl HG, Bierbaum G. Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS One 2009; 4:6788.
43. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 1999; 274:8405-10.
44. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001; 193:1067-76.